KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Cash & Current Investments: 2009-2025

Historic Cash & Current Investments for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $1.5 billion.

  • Biomarin Pharmaceutical's Cash & Current Investments rose 58.83% to $1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 billion, marking a year-over-year increase of 24.44%. This contributed to the annual value of $1.1 billion for FY2024, which is 5.95% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Cash & Current Investments stood at $1.5 billion for Q3 2025, which was up 3.19% from $1.4 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Cash & Current Investments ranged from a high of $1.5 billion in Q3 2025 and a low of $930.4 million during Q3 2024.
  • In the last 3 years, Biomarin Pharmaceutical's Cash & Current Investments had a median value of $1.2 billion in 2023 and averaged $1.2 billion.
  • In the last 5 years, Biomarin Pharmaceutical's Cash & Current Investments declined by 28.31% in 2021 and then spiked by 58.83% in 2025.
  • Biomarin Pharmaceutical's Cash & Current Investments (Quarterly) stood at $1.0 billion in 2021, then climbed by 27.39% to $1.3 billion in 2022, then dropped by 16.86% to $1.1 billion in 2023, then rose by 5.95% to $1.1 billion in 2024, then spiked by 58.83% to $1.5 billion in 2025.
  • Its last three reported values are $1.5 billion in Q3 2025, $1.4 billion for Q2 2025, and $1.3 billion during Q1 2025.